GlobeNewswire: Turning Point Therapeutics, Inc. Contains the last 10 of 119 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:50:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/08/08/2494336/0/en/Turning-Point-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-Provides-Operational-Updates.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates2022-08-08T20:17:00Z<![CDATA[SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended June 30, 2022 and provided operational updates.]]>https://www.globenewswire.com/news-release/2022/07/27/2487265/0/en/Turning-Point-Therapeutics-Provides-Regulatory-Update-for-Repotrectinib-for-the-Treatment-of-ROS1-Advanced-NSCLC.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC2022-07-27T20:05:00Z<![CDATA[Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDA Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDA]]>https://www.globenewswire.com/news-release/2022/06/24/2468792/0/en/Turning-Point-Therapeutics-and-MD-Anderson-Announce-Strategic-Alliance-to-Advance-Precision-Cancer-Therapies.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies2022-06-24T13:00:00Z<![CDATA[HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.]]>https://www.globenewswire.com/news-release/2022/05/26/2451624/0/en/Turning-Point-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics to Participate in Upcoming Investor Conferences2022-05-26T20:30:00Z<![CDATA[SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14.]]>https://www.globenewswire.com/news-release/2022/05/16/2443907/0/en/Turning-Point-Therapeutics-Announces-Appointment-of-Steve-Sabus-as-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer2022-05-16T12:30:00Z<![CDATA[SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.]]>https://www.globenewswire.com/news-release/2022/05/10/2440215/0/en/Turning-Point-Therapeutics-Reports-First-Quarter-2022-Financial-Results-Provides-Operational-Updates.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates2022-05-10T20:05:00Z<![CDATA[SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended March 31, 2022 and provided operational updates.]]>https://www.globenewswire.com/news-release/2022/05/10/2439752/0/en/Turning-Point-Therapeutics-Granted-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-With-One-Prior-ROS1-Tyrosine-Kinase-Inhibitor-and-no-Prior-Chemotherapy.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy2022-05-10T12:30:00Z<![CDATA[SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth regulatory designation, and third Breakthrough Therapy designation, to lead drug candidate repotrectinib.]]>https://www.globenewswire.com/news-release/2022/05/05/2436928/0/en/Turning-Point-Therapeutics-Announces-Pipeline-Expansion-Licensing-of-TPX-4589-LM-302-A-Clinical-Stage-Anti-Claudin18-2-Antibody-Drug-Conjugate-for-Gastrointestinal-Cancers-From-Lan.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines2022-05-05T13:00:00Z<![CDATA[Strategic Expansion of Turning Point Precision Oncology Portfolio]]>https://www.globenewswire.com/news-release/2022/04/28/2431243/0/en/Turning-Point-Therapeutics-and-Zai-Lab-Announce-Topline-Analysis-in-China-Subpopulation-for-Repotrectinib-in-ROS1-Positive-NSCLC-Cohorts-Within-Global-Phase-1-2-TRIDENT-1-Study.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study2022-04-28T11:30:00Z<![CDATA[SAN DIEGO, SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset.]]>https://www.globenewswire.com/news-release/2022/04/12/2421462/0/en/Turning-Point-Therapeutics-Announces-Positive-Topline-Data-by-Blinded-Independent-Central-Review-for-Repotrectinib-Across-All-ROS1-Positive-NSCLC-Cohorts-of-Phase-1-2-TRIDENT-1-Stu.html?f=22&fvtc=4&fvtv=54496Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study 2022-04-12T20:46:15Z<![CDATA[SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced positive topline results from the registrational TRIDENT-1 study across all four ROS1-positive advanced non-small cell lung cancer (NSCLC) cohorts, as reported by Blinded Independent Central Review (BICR).]]>